Wockhardt to Pursue Self-Commercialization of Zaynich Instead of Licensing

Wockhardt to Self-Manufacture Novel Antibiotic Zaynich in the US

Wockhardt, the Indian pharmaceutical company founded by Habil Khorakiwala, has announced that it will commercialize its novel antibiotic Zaynich in the US without partnering with a global pharmaceutical company. This decision marks a significant departure from the traditional licensing or partnership agreements often taken by Indian drugmakers to launch innovative products in developed markets.

The company has started building the commercial structure needed for the US launch, including a leadership team across medical, sales, marketing, and market access. Operational functions such as data management are being outsourced, with the leadership team in-house and operational personnel outsourced.

Zaynich, a next-generation antibiotic designed to treat drug-resistant infections, has received approvals in India and the US. The company is targeting a US launch within six to eight months, with the India rollout expected slightly earlier. The drug has also been filed in Europe, where approval is expected later this year.

Read also: Sony, 3one4 Capital Support WeRize in Latest Funding Round, Fintech Eyes 2028 Initial Public Offering

Comparative Pricing of Zaynich in the US and India

Khorakiwala expects revenues from Zaynich to begin in FY28, with a sharper scale-up in FY29. He estimates the drug's global peak sales potential at $1.5 billion to $2 billion annually, with the benchmark being the collective annual sales of newer antibiotics already on the market, which generate about $1 billion in annual sales.

Zaynich uses an "enhancer" mechanism rather than a beta-lactam inhibitor, making it different from traditional antibiotics used against resistant bacteria. The drug works rapidly, is bactericidal, and has minimal side effects.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

The company plans to market Zaynich through scientific and medical engagement rather than conventional commercial promotion. This decision is linked to Wockhardt's longer-term plan to build an innovation-led business, with the commercial organization being created for Zaynich also supporting future products from the company's pipeline.

The strategy comes as Wockhardt attempts to reposition itself after years of financial stress and sustained investment in research. Khorakiwala expects the company to undergo a major internal transformation over the next five years, with innovation and biologicals increasingly dominating revenues.